FINWIRES · TerminalLIVE
FINWIRES

在股价下跌后，Stifel Canada将Dollarama的评级上调至“买入”；目标价上调至190.00加元。

By

-- 周二，Stifel Canada将Dollarama（DOL.TO）的股票评级从“持有”上调至“买入”，并将目标股价从180加元上调至190加元，此前该公司股价出现下跌。 “Dollarama的股价接近52周低点，我们认为这为投资者提供了一个极具吸引力的入场点。我们基于以下原因将评级调整为‘买入’：(1) 其估值已从2026年1月高达39倍的预期市盈率回落至目前的29.5倍，低于两年平均水平33倍。(2) 鉴于伊朗冲突可能导致未来一年出现显著通胀，Dollarama的市场份额有望提升。为了更有效地利用手中的钱，加拿大人可能会更多地在Dollarama购物。(3) 近期内部人士的买入行为令人鼓舞。首席财务官和首席执行官近期分别以每股174美元和175美元的价格买入了股票，高于目前的价位。因此，鉴于其估值更为合理，且通胀压力可能推动Dollarama获得更大的市场份额，我们将评级调整为‘买入’，并将目标价上调10美元至190美元。”分析师Martin Landry写道。 （报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究报告。研究机构可通过以下链接联系我们：https://www..com/contact-us）

Price: $172.75, Change: $+2.26, Percent Change: +1.33%

Related Articles

Australia

American Electric Power CEO Says Speed to Market Key Issue in Load Connection

American Electric Power (AEP) CEO Bill Fehrman said Tuesday that speed to market is the main issue in efficiently connecting energy load to generation.In a Q1 earnings call, Fehrman said that, in particular, the performance and stakeholder approval process of PJM, the US mid-Atlantic grid operator, represents a major challenge."The current state of PJM's performance and stakeholder approval process does not give me great confidence that these issues will be resolved any time soon," Fehrman said on the call."In fact, if something is not done now, I expect we could still be having these same conversations in 10 years," he added.Expanding and strengthening the grid will ensure new generation resources can connect quickly, reliably, and affordably to serve the growing load, the CEO said.Price: $137.27, Change: $+2.61, Percent Change: +1.94%

$AEP
Australia

MGE Energy Q1 Earnings, Revenue Rise

MGE Energy (MGEE) reported Q1 earnings Tuesday of $1.32 per diluted share, up from $1.14 a year earlier.One analyst polled by FactSet expected $1.13.Revenue for the three months ended March 31 was $242.7 million, up from $219 million a year earlier.Price: $80.48, Change: $+0.36, Percent Change: +0.46%

$MGEE
Research

Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.

$PFE